Quick Answer
Silence Therapeutics plc reported Diluted EPS of $0.63 per share (loss) for fiscal year 2025.
Silence Therapeutics plc Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.63 | -90.9% |
| 2024 | -$0.33 | +32.7% |
| 2023 | -$0.49 | +5.8% |
| 2022 | -$0.52 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.15 | +40.0% | +21.1% |
| June 30, 2025 | -$0.19 | -35.7% | +5.0% |
| March 31, 2025 | -$0.20 | -900.0% | +20.0% |
| September 30, 2024 | -$0.25 | — | -78.6% |
| June 30, 2024 | -$0.14 | — | -600.0% |
| March 31, 2024 | -$0.02 | — | — |
- Silence Therapeutics plc showed a decrease of -90.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Silence Therapeutics plc’s diluted eps has declined by 21.2% (from $0.52 per share (loss) to $0.63 per share (loss)).
- The most recent figure is from Silence Therapeutics plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: